drugset / Trial / NCT00019695

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT00019695

Phase 2 Terminated National Cancer Institute (NCI)
Treatment

Summary

RATIONALE: Ketoconazole may suppress the production of hormones and may interfere in the growth of prostate cancer cells. Alendronate sodium may be effective in preventing bone metastases and bone pain associated with prostate cancer. It is not known if ketoconazole is more effective with or without alendronate sodium. PURPOSE: Randomized phase II trial to study the effectiveness of ketoconazole with or without alendronate sodium in treating patients who have metastatic prostate cancer.

Timeline

Start
1999-03
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule Oral
Subject Ketoconazole Small molecule Oral